Vancouver, British Columbia – February 25, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a leader in the development of psilocybin and other psychedelic compounds with broad cognitive, behavioral, and peripheral physiologic effects, has received approval for its first clinical program in Autism Spectrum Disorder (ASD). The Company has obtained Institutional Review Board (IRB) approval of its protocol for a US-based Observational Study (NM-101)...

Vancouver, British Columbia – February 18 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: LIBFF) (“NOVA” or the “Company”), a leader in the development of serotonergic psychedelic compounds, is pleased to announce that the Company is expanding its pre-clinical program to develop a novel diagnostic and treatment approach to fragile X syndrome (FXS) ...